Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.clml.2015.05.005 http://scihub22266oqcxt.onion/10.1016/j.clml.2015.05.005 C4837956!4837956!26141213     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Lymphoma+Myeloma+Leuk 2015 ; 15 (9): 556-62 Nephropedia Template TP {{tp|p=26141213|t=2015. Jumping translocations in myeloid malignancies associated with treatment resistance and poor survival |pdf=|usr=}}{{26141213}} gab.com Text Jumping translocations in myeloid malignancies associated with treatment resistance and poor survival JO: Clin Lymphoma Myeloma Leuk http://www.kidney.de/pget.php?&tw=1&pmid=26141213 #FOAvip Background: Jumping translocations (JT) are uncommon cytogenetic abnormalities involving non-reciprocal translocations of a single donor chromosome onto two or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. Materials and Methods: We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. Results: We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia (AML) with MDS-related changes, 4 cases of myelodysplastic syndrome (MDS) and 2 cases of post-polycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late ocurrence, with a median time to JT development of 24.9 months (range 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients achieving a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% CI 2.5-15.5) after identification of a JT. Conclusion: The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with patients having a poor response to treatment, disease transformation to AML and short overall survival. Twit Text FOAVip Jumping translocations in myeloid malignancies associated with treatment resistance and poor survival ????Clin Lymphoma Myeloma Leuk http://www.kidney.de/pget.php?&tw=1&pmid=26141213 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26141213 #FOAvip English Wikipedia <ref>{{Cite pmid|26141213}}</ref> Jumping translocations in myeloid malignancies associated with treatment resistance and poor survival #MMPMID26141213 Sanford D; DiNardo CD; Tang G; Cortes JE; Verstovek S; Jabbour E; Ravandi F; Kantarjian H; Garcia-Manero G Clin Lymphoma Myeloma Leuk 2015[Sep]; 15 (9): 556-62 PMID26141213show ga Background: Jumping translocations (JT) are uncommon cytogenetic abnormalities involving non-reciprocal translocations of a single donor chromosome onto two or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. Materials and Methods: We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. Results: We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia (AML) with MDS-related changes, 4 cases of myelodysplastic syndrome (MDS) and 2 cases of post-polycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late ocurrence, with a median time to JT development of 24.9 months (range 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients achieving a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% CI 2.5-15.5) after identification of a JT. Conclusion: The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with patients having a poor response to treatment, disease transformation to AML and short overall survival. äJumping translocations in myeloid malignancies associated with treatme(epmc).pdf DeepDyve Pubget Overpricing